{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:19:10Z","timestamp":1777119550260,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["221Z267"],"award-info":[{"award-number":["221Z267"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004006","name":"Bilimsel Ara\u015ftirma Projeleri Birimi, Istanbul \u00dcniversitesi","doi-asserted-by":"publisher","award":["FYL-2023-40043"],"award-info":[{"award-number":["FYL-2023-40043"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-88388-4","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T15:45:16Z","timestamp":1745336716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification of potential SARS-CoV-2 inhibitors among well-tolerated drugs using drug repurposing and in vitro approaches"],"prefix":"10.1038","volume":"15","author":[{"given":"Bet\u00fcl","family":"Oru\u00e7o\u011flu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130dil","family":"\u00c7etin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Handan","family":"\u015eim\u015fek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Top\u00e7ul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmut","family":"\u00c7al\u0131\u015fkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cihan","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130. Halil","family":"Kavakl\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alper","family":"Okyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eeref","family":"G\u00fcl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"1","key":"88388_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41392-020-0178-y","volume":"5","author":"HM Mengist","year":"2020","unstructured":"Mengist, H. M., Fan, X. & Jin, T. Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro). Signal Transduct. Target Ther. 5(1), 67 (2020).","journal-title":"Signal Transduct. Target Ther."},{"issue":"2","key":"88388_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41589-020-00689-z","volume":"17","author":"W Rut","year":"2021","unstructured":"Rut, W. et al. SARS-CoV-2 M(pro) inhibitors and activity-based probes for patient-sample imaging. Nat. Chem. Biol. 17(2), 222\u2013228 (2021).","journal-title":"Nat. Chem. Biol."},{"issue":"7811","key":"88388_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582(7811), 289\u2013293 (2020).","journal-title":"Nature"},{"issue":"7811","key":"88388_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"ZM Jin","year":"2020","unstructured":"Jin, Z. M. et al. Structure of M-pro from SARS-CoV-2 and discovery of its inhibitors. Nature 582(7811), 289 (2020).","journal-title":"Nature"},{"issue":"1","key":"88388_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41392-022-01249-8","volume":"7","author":"S Lei","year":"2022","unstructured":"Lei, S. et al. Small molecules in the treatment of COVID-19. Signal Transduct. Targ. Ther. 7(1), 387 (2022).","journal-title":"Signal Transduct. Targ. Ther."},{"issue":"13","key":"88388_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.167003","volume":"433","author":"E Arutyunova","year":"2021","unstructured":"Arutyunova, E. et al. N-terminal finger stabilizes the S1 Pocket for the reversible feline drug GC376 in the SARS-CoV-2 M(pro) dimer. J. Mol. Biol. 433(13), 167003 (2021).","journal-title":"J. Mol. Biol."},{"issue":"6497","key":"88388_CR7","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/science.abb4489","volume":"368","author":"W Dai","year":"2020","unstructured":"Dai, W. et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 368(6497), 1331\u20131335 (2020).","journal-title":"Science"},{"issue":"4","key":"88388_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3906\/biy-2012-52","volume":"45","author":"S Gul","year":"2021","unstructured":"Gul, S. In silico drug repositioning against human NRP1 to block SARS-CoV-2 host entry. Turk. J. Biol. 45(4), 442\u2013458 (2021).","journal-title":"Turk. J. Biol."},{"issue":"1","key":"88388_CR9","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/s41467-021-22362-2","volume":"12","author":"S Iketani","year":"2021","unstructured":"Iketani, S. et al. Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. Nat. Commun. 12(1), 2016 (2021).","journal-title":"Nat. Commun."},{"issue":"4","key":"88388_CR10","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","volume":"181","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 181(4), 894\u2013904 (2020).","journal-title":"Cell"},{"issue":"6489","key":"88388_CR11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science 368(6489), 409\u2013412 (2020).","journal-title":"Science"},{"issue":"1","key":"88388_CR12","doi-asserted-by":"publisher","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","volume":"12","author":"B Boras","year":"2021","unstructured":"Boras, B. et al. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Nat. Commun. 12(1), 6055 (2021).","journal-title":"Nat. Commun."},{"issue":"1","key":"88388_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-18233-x","volume":"11","author":"LF Fu","year":"2020","unstructured":"Fu, L. F. et al. Both boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nat. Commun. 11(1), 1\u20138 (2020).","journal-title":"Nat. Commun."},{"issue":"2","key":"88388_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4155\/fmc-2020-0236","volume":"13","author":"E De Vita","year":"2021","unstructured":"De Vita, E. 10 years into the resurgence of covalent drugs. Fut. Medicinal Chem. 13(2), 193\u2013210 (2021).","journal-title":"Fut. Medicinal Chem."},{"issue":"4","key":"88388_CR15","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1021\/acs.jmedchem.1c00598","volume":"65","author":"SH Han","year":"2022","unstructured":"Han, S. H. et al. Structure-based optimization of ML300-derived, noncovalent inhibitors targeting the severe acute respiratory syndrome coronavirus 3CL protease (SARS-CoV-2 3CL). J. Medicinal Chem. 65(4), 2880\u20132904 (2022).","journal-title":"J. Medicinal Chem."},{"issue":"2","key":"88388_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/v13020174","volume":"13","author":"GJ Lockbaum","year":"2021","unstructured":"Lockbaum, G. J. et al. Crystal structure of SARS-CoV-2 main protease in complex with the non-covalent inhibitor ML188. Viruses-Basel 13(2), 174 (2021).","journal-title":"Viruses-Basel"},{"issue":"17","key":"88388_CR17","doi-asserted-by":"publisher","first-page":"6772","DOI":"10.1080\/07391102.2020.1802346","volume":"39","author":"S Gul","year":"2021","unstructured":"Gul, S. et al. In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials. J. Biomol. Struct. Dyn. 39(17), 6772\u20136791 (2021).","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"3","key":"88388_CR18","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01837-21","volume":"96","author":"J Malicoat","year":"2022","unstructured":"Malicoat, J. et al. Development of a single-cycle infectious SARS-CoV-2 virus replicon particle system for use in biosafety level 2 laboratories. J. Virol. 96(3), e0183721 (2022).","journal-title":"J. Virol."},{"issue":"15","key":"88388_CR19","doi-asserted-by":"publisher","first-page":"e2025866118","DOI":"10.1073\/pnas.2025866118","volume":"118","author":"X He","year":"2021","unstructured":"He, X. et al. Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing. Proceedings of the National Academy of Sciences of the United States of America 118(15), e2025866118 (2021).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"88388_CR20","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s12250-021-00385-9","volume":"36","author":"YY Jin","year":"2021","unstructured":"Jin, Y. Y. et al. A convenient and biosafe replicon with accessory genes of SARS-CoV-2 and its potential application in antiviral drug discovery. Virologica Sinica 36(5), 913\u2013923 (2021).","journal-title":"Virologica Sinica"},{"issue":"1","key":"88388_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1113\/jphysiol.2008.164400","volume":"587","author":"A Adamantidis","year":"2009","unstructured":"Adamantidis, A. & de Lecea, L. The hypocretins as sensors for metabolism and arousal. J. Physiol. -London 587(1), 33\u201340 (2009).","journal-title":"J. Physiol. -London"},{"key":"88388_CR22","doi-asserted-by":"publisher","first-page":"104974","DOI":"10.1016\/j.antiviral.2020.104974","volume":"185","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2. Antiviral Res. 185, 104974 (2021).","journal-title":"Antiviral Res."},{"key":"88388_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-1-61779-108-6_6","volume":"740","author":"N Ke","year":"2011","unstructured":"Ke, N. et al. The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol. Biol. 740, 33\u201343 (2011).","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"88388_CR24","doi-asserted-by":"publisher","first-page":"18510","DOI":"10.1038\/s41598-021-97962-5","volume":"11","author":"S Gul","year":"2021","unstructured":"Gul, S. et al. Structure-based design and classifications of small molecules regulating the circadian rhythm period. Sci. Rep. 11(1), 18510 (2021).","journal-title":"Sci. Rep."},{"key":"88388_CR25","doi-asserted-by":"crossref","unstructured":"Owen, C. D., Lukacik, P., Strain-Damerell, C. M., Douangamath, A., Powell, A. J., Fearon, D., Brandao-Neto, J., Crawshaw, A. D., Aragao, D., Williams, M., Flaig, R., Hall, D. R., McAuley, K. E., Mazzorana, M., Stuart, D. I., von Delft, F. & Walsh, M. A., COVID-19 main proteasewith unliganded active site (2019-nCoV, coronavirus disease 2019,SARS-CoV-2). CSB Protein Data Bank (PDB) ID, 6Y84, 3\u20137. (2020).","DOI":"10.2210\/pdb6yb7\/pdb"},{"issue":"2","key":"88388_CR26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31(2), 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"issue":"1","key":"88388_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey, W., Dalke, A. & Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph. 14(1), 33\u20138 (1996).","journal-title":"J. Mol. Graph."},{"issue":"1","key":"88388_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nmeth.4067","volume":"14","author":"J Huang","year":"2017","unstructured":"Huang, J. et al. CHARMM36m: An improved force field for folded and intrinsically disordered proteins. Nat. Methods 14(1), 71\u201373 (2017).","journal-title":"Nat. Methods"},{"issue":"16","key":"88388_CR29","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1002\/jcc.20289","volume":"26","author":"JC Phillips","year":"2005","unstructured":"Phillips, J. C. et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26(16), 1781\u20131802 (2005).","journal-title":"J. Comput. Chem."},{"issue":"21","key":"88388_CR30","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/jcc.24829","volume":"38","author":"S Kim","year":"2017","unstructured":"Kim, S. et al. CHARMM-GUI ligand reader and modeler for CHARMM force field generation of small molecules. J. Comput. Chem. 38(21), 1879\u20131886 (2017).","journal-title":"J. Comput. Chem."},{"issue":"8","key":"88388_CR31","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","volume":"30","author":"CL Ma","year":"2020","unstructured":"Ma, C. L. et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 30(8), 678\u2013692 (2020).","journal-title":"Cell Res."},{"key":"88388_CR32","unstructured":"NCIRD. Types of COVID-19 Treatment. 2024 07\/12\/2024 [cited 2024 08\/25\/2024]; Available from: https:\/\/www.cdc.gov\/covid\/treatment\/index.html."},{"key":"88388_CR33","unstructured":"International Transporter, C., et al., Membrane transporters in drug development. Nat. Rev. Drug Discov., 9(3), 215\u201336, (2010)."},{"issue":"10","key":"88388_CR34","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1124\/dmd.111.040477","volume":"39","author":"Y Yabe","year":"2011","unstructured":"Yabe, Y., Galetin, A. & Houston, J. B. Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab. Dispos. 39(10), 1808\u20131814 (2011).","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"88388_CR35","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1124\/dmd.115.066647","volume":"44","author":"HC Chien","year":"2016","unstructured":"Chien, H. C. et al. Rapid method to determine intracellular drug concentrations in cellular uptake assays: Application to metformin in organic cation transporter 1-transfected human embryonic kidney 293 Cells. Drug Metab. Dispos. 44(3), 356\u2013364 (2016).","journal-title":"Drug Metab. Dispos."},{"issue":"22","key":"88388_CR36","first-page":"6175","volume":"52","author":"M Nakagawa","year":"1992","unstructured":"Nakagawa, M. et al. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res. 52(22), 6175\u20136181 (1992).","journal-title":"Cancer Res."},{"issue":"5","key":"88388_CR37","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1124\/dmd.111.044289","volume":"40","author":"KR Korzekwa","year":"2012","unstructured":"Korzekwa, K. R. et al. Models to predict unbound intracellular drug concentrations in the presence of transporters. Drug Metab. Dispos. 40(5), 865\u2013876 (2012).","journal-title":"Drug Metab. Dispos."},{"issue":"12","key":"88388_CR38","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1124\/dmd.110.035824","volume":"38","author":"HS Brown","year":"2010","unstructured":"Brown, H. S. et al. Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: Transporter-enzyme interplay. Drug Metab. Dispos. 38(12), 2139\u20132146 (2010).","journal-title":"Drug Metab. Dispos."},{"issue":"9","key":"88388_CR39","doi-asserted-by":"publisher","first-page":"T83","DOI":"10.1530\/ERC-17-0003","volume":"24","author":"J Shi","year":"2017","unstructured":"Shi, J. & Mitchison, T. J. Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic. Endocrine-Related Cancer 24(9), T83 (2017).","journal-title":"Endocrine-Related Cancer"},{"key":"88388_CR40","doi-asserted-by":"crossref","unstructured":"Vatansever, E. C., et al., Bepridil is potent against SARS-CoV-2 in vitro. Proceedings of the National Academy of Sciences of the United States of America, 118(10), (2021).","DOI":"10.1073\/pnas.2012201118"},{"key":"88388_CR41","doi-asserted-by":"publisher","first-page":"755600","DOI":"10.3389\/fphar.2021.755600","volume":"12","author":"SM Fred","year":"2022","unstructured":"Fred, S. M. et al. Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine shows antiviral activity against the novel variants. Front. Pharmacol. 12, 755600 (2022).","journal-title":"Front. Pharmacol."},{"key":"88388_CR42","doi-asserted-by":"crossref","unstructured":"Alkafaas, S. S., et al., Molecular docking as a tool for the discovery of novel insight about the role of acid sphingomyelinase inhibitors in SARS- CoV-2 infectivity. Bmc Public Health, 24(1), (2024).","DOI":"10.1186\/s12889-024-17747-z"},{"issue":"14","key":"88388_CR43","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.1080\/07391102.2022.2107573","volume":"41","author":"SK Sankaran","year":"2023","unstructured":"Sankaran, S. K. & Nair, A. S. Molecular dynamics and docking studies on potentially active natural phytochemicals for targeting SARS-CoV-2 main protease. J. Biomol. Struct. Dyn. 41(14), 6459\u20136475 (2023).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"88388_CR44","doi-asserted-by":"crossref","unstructured":"Honrubia, J. M., et al., SARS-CoV-2-mediated lung edema and replication are diminished by cystic fibrosis transmembrane conductance regulator modulators. Mbio, 14(1), (2023).","DOI":"10.1128\/mbio.03136-22"},{"key":"88388_CR45","doi-asserted-by":"crossref","unstructured":"Gruden, G., et al., Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: A case report. Therapeutic Adv. Hematol., 12, (2021).","DOI":"10.1177\/20406207211011353"},{"issue":"4","key":"88388_CR46","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1007\/s11239-021-02604-2","volume":"53","author":"G Maraziti","year":"2022","unstructured":"Maraziti, G. & Becattini, C. Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia. J. Thrombosis Thrombol. 53(4), 954\u2013958 (2022).","journal-title":"J. Thrombosis Thrombol."},{"key":"88388_CR47","doi-asserted-by":"crossref","unstructured":"Elkahloun, A. G. & Saavedra, J.M. Candesartan could ameliorate the COVID-19 cytokine storm. Biomed. Pharmacother., 131, (2020).","DOI":"10.1016\/j.biopha.2020.110653"},{"issue":"44","key":"88388_CR48","doi-asserted-by":"publisher","first-page":"27381","DOI":"10.1073\/pnas.2010470117","volume":"117","author":"Z Li","year":"2020","unstructured":"Li, Z. et al. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. Proc. Natl. Acad. Sci. USA 117(44), 27381\u201327387 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"88388_CR49","doi-asserted-by":"publisher","first-page":"e2024420118","DOI":"10.1073\/pnas.2024420118","volume":"118","author":"C Ma","year":"2021","unstructured":"Ma, C. & Wang, J. Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors. Proc. Natl. Acad. Sci. USA 118(8), e2024420118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88388-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88388-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88388-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T17:02:19Z","timestamp":1745341339000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88388-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["88388"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-88388-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13975"}}